LINEAGE CELL THERAPEUTICS IN (LCTX)

US53566P1093 - Common Stock

0.558  +0.06 (+11.16%)

Premarket: 0.5822 +0.02 (+4.34%)

Fundamental Rating

2

LCTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. LCTX has a bad profitability rating. Also its financial health evaluation is rather negative. LCTX is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

LCTX had negative earnings in the past year.
In the past year LCTX has reported a negative cash flow from operations.
LCTX had negative earnings in each of the past 5 years.
In the past 5 years LCTX reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of LCTX (-20.82%) is better than 76.33% of its industry peers.
With a decent Return On Equity value of -30.39%, LCTX is doing good in the industry, outperforming 78.83% of the companies in the same industry.
Industry RankSector Rank
ROA -20.82%
ROE -30.39%
ROIC N/A
ROA(3y)-22.39%
ROA(5y)-19.13%
ROE(3y)-38.79%
ROE(5y)-29.64%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

LCTX has a Gross Margin of 95.00%. This is amongst the best in the industry. LCTX outperforms 95.55% of its industry peers.
LCTX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for LCTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.54%
GM growth 5Y-0.32%

More info and screens

3

2. Health

2.1 Basic Checks

LCTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LCTX has more shares outstanding
LCTX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LCTX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -3.80, we must say that LCTX is in the distress zone and has some risk of bankruptcy.
LCTX's Altman-Z score of -3.80 is in line compared to the rest of the industry. LCTX outperforms 43.24% of its industry peers.
LCTX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LCTX (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.8
ROIC/WACCN/A
WACC10.91%

2.3 Liquidity

A Current Ratio of 2.48 indicates that LCTX has no problem at all paying its short term obligations.
The Current ratio of LCTX (2.48) is worse than 70.64% of its industry peers.
A Quick Ratio of 2.48 indicates that LCTX has no problem at all paying its short term obligations.
LCTX's Quick ratio of 2.48 is on the low side compared to the rest of the industry. LCTX is outperformed by 69.57% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.48

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.69% over the past year.
Looking at the last year, LCTX shows a decrease in Revenue. The Revenue has decreased by -0.81% in the last year.
LCTX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.38% yearly.
EPS 1Y (TTM)7.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-0.81%
Revenue growth 3Y69.71%
Revenue growth 5Y12.38%
Sales Q2Q%203.29%

3.2 Future

LCTX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.31% yearly.
The Revenue is expected to grow by 58.17% on average over the next years. This is a very strong growth
EPS Next Y-2%
EPS Next 2Y-7.28%
EPS Next 3Y-7.88%
EPS Next 5Y-3.31%
Revenue Next Year-45.06%
Revenue Next 2Y10.82%
Revenue Next 3Y38.45%
Revenue Next 5Y58.17%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LCTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LCTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

LCTX's earnings are expected to decrease with -7.88% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.28%
EPS Next 3Y-7.88%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LCTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LINEAGE CELL THERAPEUTICS IN

NYSEARCA:LCTX (12/20/2024, 8:21:56 PM)

Premarket: 0.5822 +0.02 (+4.34%)

0.558

+0.06 (+11.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners50.34%
Inst Owner Change0.16%
Ins Owners0.44%
Ins Owner Change1.94%
Market Cap122.99M
Analysts81.43
Price Target4.66 (735.13%)
Short Float %9.78%
Short Ratio9.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.16%
Min EPS beat(2)36.06%
Max EPS beat(2)54.25%
EPS beat(4)3
Avg EPS beat(4)29.84%
Min EPS beat(4)-2.31%
Max EPS beat(4)54.25%
EPS beat(8)7
Avg EPS beat(8)25.69%
EPS beat(12)8
Avg EPS beat(12)-5.87%
EPS beat(16)11
Avg EPS beat(16)8.78%
Revenue beat(2)2
Avg Revenue beat(2)150.48%
Min Revenue beat(2)42.42%
Max Revenue beat(2)258.54%
Revenue beat(4)4
Avg Revenue beat(4)90.34%
Min Revenue beat(4)4.11%
Max Revenue beat(4)258.54%
Revenue beat(8)6
Avg Revenue beat(8)42.77%
Revenue beat(12)8
Avg Revenue beat(12)28.78%
Revenue beat(16)11
Avg Revenue beat(16)40.65%
PT rev (1m)-3.03%
PT rev (3m)-8.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1366.8%
EPS NY rev (1m)0%
EPS NY rev (3m)14.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-86.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.11
P/FCF N/A
P/OCF N/A
P/B 1.86
P/tB 13.71
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.04
BVpS0.3
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.82%
ROE -30.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95%
FCFM N/A
ROA(3y)-22.39%
ROA(5y)-19.13%
ROE(3y)-38.79%
ROE(5y)-29.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.54%
GM growth 5Y-0.32%
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.67%
Cap/Sales 3.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.48
Altman-Z -3.8
F-Score4
WACC10.91%
ROIC/WACCN/A
Cap/Depr(3y)64.6%
Cap/Depr(5y)42.14%
Cap/Sales(3y)6.13%
Cap/Sales(5y)6.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-2%
EPS Next 2Y-7.28%
EPS Next 3Y-7.88%
EPS Next 5Y-3.31%
Revenue 1Y (TTM)-0.81%
Revenue growth 3Y69.71%
Revenue growth 5Y12.38%
Sales Q2Q%203.29%
Revenue Next Year-45.06%
Revenue Next 2Y10.82%
Revenue Next 3Y38.45%
Revenue Next 5Y58.17%
EBIT growth 1Y9.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.48%
EBIT Next 3Y10.14%
EBIT Next 5Y-0.37%
FCF growth 1Y-889.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-752.21%
OCF growth 3YN/A
OCF growth 5YN/A